Zacks.com on MSN8h
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
GlobalData on MSN18h
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Zacks.com on MSN9h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline SetbackThe third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...
GlobalData on MSN18h
Ross Memorial Hospital expands to enhance emergency care in OntarioRoss Memorial Hospital in Kawartha Lakes, Ontario, Canada, is set to undergo the expansion and renovation of its emergency ...
Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback